• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nexstim

9.95 EUR

-0.50 %

5,652 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-0.50 %
+8.15 %
+12.56 %
-29.93 %
-29.43 %
+0.10 %
+175.62 %
+121.21 %
-98.36 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
80.34M EUR
Turnover
49.25K EUR
P/E (adj.) (26e)
79.67
EV/EBIT (adj.) (26e)
64.69
P/B (26e)
7.86
EV/S (26e)
6.15
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
14.05.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 15.05.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
Interesting insights from Brainlab CEO Rainer Birkenbach on LinkedIn: LinkedIn #medtech #neurosurgery #innovation #dldhealth | Rainer Birkenbach Today was one of those moments I will never forget. At the DLD Conference in Munich, I had the privilege of speaking about the range of...
6/12/2026, 3:45 PM
33
By the end of H1 last year, 14 deals had been announced. So far this year, 15 deals have been announced, and there is still one month left. Of course, the units sold this year have been the more expensive NBS 6 versions, so the revenue generated by them has likely been higher as ...
6/11/2026, 9:29 AM
by Kyhnykeisari
19
Here are Antti’s comments regarding the massive one-off order received by Nexstim Nexstim announced on Thursday that it has received an order for ten NBS 6 systems from its distributor. The systems will be delivered to the United States and Europe during the first and second halves...
6/12/2026, 5:40 AM
by Sijoittaja-alokas
17
Yes, exactly, I mentioned it a bit briefly there. The >20% growth guided by management will definitely be achieved in H1.
6/11/2026, 8:25 AM
by AccionHombre
12
When thinking about BCI (Brain-Computer Interface), the topic should probably be divided into two different areas: intracranial and extracranial entities. Intracranial, such as these implants (I wonder if they are Neuralink’s gear), is quite demanding and expensive (currently) as...
21 hours ago
by AccionHombre
11
Hello Kyhnykeisari. To get my own bookkeeping in order, would you mind checking which 2025 order announcements (H1) I am missing. Sinaptica is not included in my figures. 09.01. 1 pc. USA 10.01. 2. Canada 17.02. 1. Europe 28.03. 1. USA 26.05. 1. Europe 04.06. 1. USA 05.06. 1. Hong...
6/11/2026, 12:56 PM
by Taitoo
9
The difference of three units is explained by the devices delivered to Sinaptica. There aren’t exact dates for those, but I have personally concluded that one device was delivered in January and the order for a couple of devices was agreed upon at some point during H1.
6/11/2026, 1:06 PM
by Kyhnykeisari
8
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8
2026

Interim report Q2'26

Significant one-time order for Nexstim
Analyst Comment6/12/2026, 6:28 AM by
Antti Siltanen

Significant one-time order for Nexstim

The one-time order for ten systems strengthens our confidence in this year's growth estimates.

Nexstim
Press release6/11/2026, 6:00 AM

Nexstim Receives Order for Ten NBS 6 Systems from Distributor

Nexstim
Nexstim received a new sales authorization for the NBS 6 system in Australia
Analyst Comment6/4/2026, 5:48 AM by
Antti Siltanen

Nexstim received a new sales authorization for the NBS 6 system in Australia

The sales authorization expands the use of the NBS 6 system to diagnostics and rehabilitation.

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/3/2026, 7:00 AM

Nexstim granted authorization for commercial distribution of NBS System 6 for use in diagnostics and post-operative rehabilitation in Australia

Nexstim
Regulatory press release5/25/2026, 6:00 AM

Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register

Nexstim
Regulatory press release5/18/2026, 2:00 PM

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release5/15/2026, 11:40 AM

Nexstim Plc: Managers’ Transactions, Järnefelt

Nexstim
Regulatory press release5/15/2026, 11:40 AM

Nexstim Plc: Managers’ Transactions, Hannula

Nexstim
Regulatory press release5/15/2026, 11:40 AM

Nexstim Plc: Managers’ Transactions, Niemistö

Nexstim
Regulatory press release5/15/2026, 11:40 AM

Nexstim Plc: Managers’ Transactions, Laine

Nexstim
Nexstim strengthens its balance sheet
Research5/15/2026, 6:00 AM by
Antti Siltanen

Nexstim strengthens its balance sheet

The 5 MEUR financing supports the growth strategy.

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Hildén

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Karvinen

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Forss

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Juokslahti

Nexstim
Regulatory press release5/13/2026, 12:00 PM

Nexstim Plc: Disclosure of change in holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release5/13/2026, 6:05 AM

Inside Information: Nexstim Plc Announces EUR 5 Million Investment from Eiffel and from Brainlab and Conversion of Options by Certain Option Holders

Nexstim
Press release5/5/2026, 6:00 AM

Nexstim Receives NBS 6 System Order from Children’s Hospital in the U.S.

Nexstim
Nexstim Q1'26: The year started with three system deliveries
Analyst Comment4/29/2026, 6:38 AM by
Antti Siltanen

Nexstim Q1'26: The year started with three system deliveries

The seasonally quiet start to the year proceeded as expected.

Nexstim